Bioxytran, Inc., a biotechnology firm specializing in galectin-targeting carbohydrate technologies, has signed a commercial distribution agreement with Khoury Medical LTD for the distribution of its dietary supplement, A-SUQAR.
The agreement allows Khoury Medical to commercialize A-SUQAR, a chewable supplement aimed at supporting healthy post-meal blood sugar levels, in permitted markets. Bioxytran's CEO, David Platt, emphasized the significance of this milestone as the company transitions towards generating recurring commercial revenue.
A-SUQAR is based on Bioxytran's proprietary partially hydrolyzed guar gum formulation and aligns with the company's broader galectin-targeting platform, which supports both pharmaceutical and nutraceutical applications.
Manufacturing will be managed by Bioxytran's designated original equipment manufacturer, while Khoury Medical will handle regulatory registration, marketing, and distribution. This collaboration aims to maintain a capital-efficient commercial model for Bioxytran, which retains full ownership of its intellectual property.
Nassar Khoury, CEO of Khoury Medical, expressed optimism about the partnership, highlighting the potential for market expansion and the product's ability to meet consumer needs. The agreement, however, is limited to non-pharmaceutical dietary products, preserving Bioxytran's capacity to independently pursue pharmaceutical and antiviral developments.
Bioxytran's recent positive Phase 2 clinical results with ProLectin-M, its antiviral candidate, further validate the company's carbohydrate-based galectin platform. The initial commercial shipments of A-SUQAR are expected to commence following standard launch preparations, targeting a significant global market demand.
Forward-looking statements in the announcement indicate expectations for the commercialization of A-SUQAR and potential benefits from the distribution agreement. However, these statements are subject to risks and uncertainties, including regulatory compliance and market acceptance.
Comments are closed.